1) Ⅷfactor staining
Ⅷ因子染色
2) Factor Ⅷ
因子Ⅷ
1.
Objective To evaluate the pathophysiological role of coagulation factor Ⅶ clotting activity (FⅦ:C),coagulation factor Ⅷ clotting activity (FⅧ:C) and fibrinogen (Fg) in patients with coronary heart disease (CHD);to study the relationship among them and co-relation with other cardiovascular risk factors;and to explore its potential clinical significance.
目的通过检测血浆中凝血因子Ⅶ促凝活性(FⅦ:C)、凝血因子Ⅷ促凝活性(FⅧ:C)及纤维蛋白原(Fg)水平来研究三者与冠状动脉性心脏病(CHD)的关系、并初步探讨冠心病患者血浆中三者间以及与其他心血管危险因子的相关性及潜在临床意义。
2.
Method Growth number, growth cycle phase, and the characteristics of endothelial cells(factor Ⅷ related antigen) of PAEC were investigated during hypoxia using the PAEC cultured in vitro as a model.
因子Ⅷ相关抗原 (ⅧR :Ag)阳性细胞数在缺氧过程中均呈明显下降 (P <0 。
3.
Objective To screen for factor Ⅷ inhibitor in patients with hemophilia A(HA) and explore the environmental risk factors for inhibitor development.
目的调查血友病A(HA)患者因子Ⅷ(FⅧ)抑制物的检出率,初步探讨抑制物产生的环境因素。
3) Factor VIII(FVIII)
因子Ⅷ(FⅧ)
4) Ⅷ-RA
Ⅷ因子
1.
EXPRESSION OF CD105, CD34, AND Ⅷ-RA IN ENDOMETRIUM IN DIFFERENT STATUS;
CD105、CD34及Ⅷ因子在不同生理状态下子宫内膜中的表达
2.
EXPRESSION DIFFERENCE AND SIGNIFICANCE OF CD105, CD34 AND Ⅷ-RA IN AUTOPSY SPECIMENS;
尸体解剖标本中CD105、CD34及Ⅷ因子表达的差异及意义
5) Factor Ⅷ
Ⅷ因子
1.
Objective To establish method of quantitive detection if active factor Ⅷ and investigation of infectious disease relating with Hematophilia.
目的 建立血友病甲体内Ⅷ因子活性定量检测方法,了解我省血友病甲患者中相关传染病情况。
2.
The antigen CD34 and the factor Ⅷ were checked by S-P immunohistochemical staining.
用免疫组化法对增殖细胞分别进行Ⅷ因子和ＣＯ３４相关抗原的检测。
6) Ⅷ factor
Ⅷ因子
1.
Results The primary culture cells from human umbilical vein were observed completely wall sticked in 24h,4-5d later,they fused like some structure of monolayer flagstone,and the Ⅷ factor associated antigens′ fluorescence staining confirmed that the cultured cells were endothelial cells.
采用形态学观察和荧光染色Ⅷ因子相关抗原,鉴定血管内皮细胞,用RT-PCR检测肿瘤血管内皮细胞标志物(TEM)的表达,采用迁徙试验、透射电镜、流式细胞仪细胞周期分析等方法检测、比较HUVEC和Td-EC的生物学特性。
2.
New microvessel density around infarct myocardium of acute MI rats was detected by immunohistochemistry with Ⅷ factor.
Ⅷ因子免疫组化染色后对各组大鼠梗死边缘区微血管进行计数;免疫组化技术及Western blot技术检测各组缺血心肌VEGF蛋白质水平表达变化;逆转录多聚酶链反应(RT-PCR)法检测缺血心肌VEGFmR-NA表达变化。
补充资料：[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式：C16H16ClN3O3S
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条